CLDF Podcast

About CLDF Podcast

The official podcast channel for the Chronic Liver Disease Foundation.

Publisher

Chronic Liver Disease Foundation

Category

health & fitness

Language

en

Explicit

No

First episode

6 May 2024

Latest episode

24 Sept 2026

Latest episodes

67 episodes in the feed.

1. 

   24 Sept 2026

   Viral Hepatitis Guideline Update

   Explore the evolving management of chronic hepatitis B (HBV) with Drs. Ira Jacobson, Paul Martin, and Robert Gish in the first installment of the What’s New in Hepatitis B series. This case-based discussion reviews hepatitis B treatment guidelines, comparing published recommendations with the panel’s perspectives on antiviral treatment eligibility, HBV DNA and ALT thresholds, and managing patients with high viral loads and normal liver enzymes or indeterminate-phase disease. The experts also address shared decision-making and the importance of considering stigma, quality of life, and patient preferences when discussing treatment. Additional topics include low-level viremia, quantitative hepatitis B surface antigen (HBsAg) testing, emerging approaches to functional cure, and considerations for discontinuing antiviral therapy in selected patients. The conversation concludes with hepatocellular carcinoma (HCC) surveillance, including monitoring after HBsAg loss and the challenges of applying age-based screening recommendations to individual patients. Gain practical perspectives on hepatitis B risk assessment, treatment decisions, and patient-centered care through expert discussion of complex clinical cases.

2. 

   22 Sept 2026

   Linerixibat Medication Review

   Christina Hanson, FNP, and Dr. Marcelo Kugelmas of South Denver Gastroenterology review linerixibat, an ileal bile acid transporter (IBAT) inhibitor, and its role in managing cholestatic pruritus in primary biliary cholangitis (PBC). This medication review podcast explores how blocking bile acid reabsorption in the ileum targets a pathway involved in persistent itching. The discussion covers the phase 2 GLIMMER study and phase 3 GLISTEN trial, including findings on itch reduction, sleep interference, and treatment response in patients with moderate to severe pruritus. The speakers also examine safety and tolerability considerations, including diarrhea, abdominal pain, nausea, elevated liver enzymes, and treatment discontinuation. Additional topics include preliminary results from the linerixibat long-term safety and tolerability study (LLSAT), maintenance of itch relief, and the need for further research on combining linerixibat with PPAR agonists. Designed for nurse practitioners, physician assistants, and other gastroenterology and hepatology professionals, this episode offers a clinical perspective on IBAT inhibitor therapy, persistent PBC-related itching, and the balance between symptom improvement and treatment tolerability. Clarifications and context within the video 👇 Linerixibat, an IBAT inhibitor, is the first FDA approved treatment for cholestatic pruritus in adults with PBC. WI-NRS is used to assess itch severity on a scale of 0-10. At 6:43, correction regarding the diagnosis of cirrhosis: It was 10% in the placebo group and 11% in the linerixibat group. At 10:24, the primary endpoints of the LLSAT study are frequency and severity of adverse events. At 11:20, the LLSAT mean WI-NRS reduction of 4.87 is for patients assigned to linerixibat in GLISTEN Part A and Part B after 52 weeks of continuous treatment.

3. 

   15 Sept 2026

   Managing Fatigue and Pruritus in Your Patients With PBC

   How can clinicians better recognize and manage itching and fatigue in primary biliary cholangitis (PBC)? In this podcast, hepatology clinicians from RUSH University Medical Center discuss the impact of PBC-related pruritus and fatigue on sleep, daily activities, and quality of life. The conversation explores proactive symptom screening, assessing itch severity, and individualizing treatment with options such as cholestyramine, PPAR therapies, rifampin, and sertraline. The speakers discuss how their treatment approaches have evolved and why ongoing communication helps identify when symptom management needs to change. For patients experiencing PBC fatigue, they address evaluating contributing factors such as thyroid dysfunction, vitamin D deficiency, and anemia, along with sleep hygiene, exercise, and realistic expectations for treatment. Throughout the discussion, they emphasize that symptom severity does not necessarily reflect liver disease progression or biochemical response. This episode highlights the importance of looking beyond liver tests, validating patients’ experiences, and encouraging patient advocacy and support networks as part of comprehensive PBC care.

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Spotify

5.0 / 5

1 ratings

Contact CLDF Podcast

Guest appearances

Does not typically book guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.